Logo image of SNDX

SYNDAX PHARMACEUTICALS INC (SNDX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SNDX - US87164F1057 - Common Stock

21.6 USD
-0.1 (-0.46%)
Last: 12/24/2025, 8:01:35 PM
21.31 USD
-0.29 (-1.34%)
After Hours: 12/24/2025, 8:01:35 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SNDX. SNDX was compared to 530 industry peers in the Biotechnology industry. SNDX has a bad profitability rating. Also its financial health evaluation is rather negative. SNDX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SNDX had negative earnings in the past year.
SNDX had a negative operating cash flow in the past year.
SNDX had negative earnings in 4 of the past 5 years.
In the past 5 years SNDX reported 4 times negative operating cash flow.
SNDX Yearly Net Income VS EBIT VS OCF VS FCFSNDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

Looking at the Return On Assets, with a value of -56.44%, SNDX is in line with its industry, outperforming 44.34% of the companies in the same industry.
SNDX has a Return On Equity of -269.78%. This is in the lower half of the industry: SNDX underperforms 71.89% of its industry peers.
Industry RankSector Rank
ROA -56.44%
ROE -269.78%
ROIC N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
SNDX Yearly ROA, ROE, ROICSNDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With an excellent Gross Margin value of 95.44%, SNDX belongs to the best of the industry, outperforming 95.47% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for SNDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNDX Yearly Profit, Operating, Gross MarginsSNDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SNDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNDX has more shares outstanding than it did 1 year ago.
SNDX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SNDX is higher compared to a year ago.
SNDX Yearly Shares OutstandingSNDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SNDX Yearly Total Debt VS Total AssetsSNDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -1.78, we must say that SNDX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.78, SNDX perfoms like the industry average, outperforming 50.94% of the companies in the same industry.
SNDX has a Debt/Equity ratio of 2.78. This is a high value indicating a heavy dependency on external financing.
SNDX's Debt to Equity ratio of 2.78 is on the low side compared to the rest of the industry. SNDX is outperformed by 81.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.78
Debt/FCF N/A
Altman-Z -1.78
ROIC/WACCN/A
WACC8.49%
SNDX Yearly LT Debt VS Equity VS FCFSNDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 4.64 indicates that SNDX has no problem at all paying its short term obligations.
SNDX has a Current ratio (4.64) which is comparable to the rest of the industry.
SNDX has a Quick Ratio of 4.42. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.42, SNDX perfoms like the industry average, outperforming 52.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.64
Quick Ratio 4.42
SNDX Yearly Current Assets VS Current LiabilitesSNDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 0.55% over the past year.
SNDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 597.19%.
Measured over the past years, SNDX shows a very strong growth in Revenue. The Revenue has been growing by 73.64% on average per year.
EPS 1Y (TTM)0.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)597.19%
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%266.97%

3.2 Future

The Earnings Per Share is expected to grow by 21.57% on average over the next years. This is a very strong growth
SNDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 57.94% yearly.
EPS Next Y14.66%
EPS Next 2Y23.95%
EPS Next 3Y24.84%
EPS Next 5Y21.57%
Revenue Next Year73.17%
Revenue Next 2Y93.15%
Revenue Next 3Y78.88%
Revenue Next 5Y57.94%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SNDX Yearly Revenue VS EstimatesSNDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
SNDX Yearly EPS VS EstimatesSNDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SNDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDX Price Earnings VS Forward Price EarningsSNDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNDX Per share dataSNDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as SNDX's earnings are expected to grow with 24.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.95%
EPS Next 3Y24.84%

More info and screens

0

5. Dividend

5.1 Amount

SNDX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SYNDAX PHARMACEUTICALS INC

NASDAQ:SNDX (12/24/2025, 8:01:35 PM)

After market: 21.31 -0.29 (-1.34%)

21.6

-0.1 (-0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners119.98%
Inst Owner Change-1.6%
Ins Owners1.12%
Ins Owner Change-0.26%
Market Cap1.88B
Revenue(TTM)111.55M
Net Income(TTM)-311.41M
Analysts87
Price TargetN/A
Short Float %29.4%
Short Ratio8.63
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.08%
Min EPS beat(2)4.24%
Max EPS beat(2)19.92%
EPS beat(4)3
Avg EPS beat(4)-79.67%
Min EPS beat(4)-370.62%
Max EPS beat(4)27.8%
EPS beat(8)7
Avg EPS beat(8)-34.32%
EPS beat(12)11
Avg EPS beat(12)-20.09%
EPS beat(16)15
Avg EPS beat(16)19.64%
Revenue beat(2)1
Avg Revenue beat(2)16.23%
Min Revenue beat(2)-6.26%
Max Revenue beat(2)38.73%
Revenue beat(4)2
Avg Revenue beat(4)-5.66%
Min Revenue beat(4)-91.24%
Max Revenue beat(4)38.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.99%
PT rev (3m)2.32%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)4.91%
EPS NY rev (1m)0.2%
EPS NY rev (3m)2.84%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)0.95%
Revenue NY rev (1m)-2.24%
Revenue NY rev (3m)-2.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.83
P/FCF N/A
P/OCF N/A
P/B 16.26
P/tB 16.26
EV/EBITDA N/A
EPS(TTM)-3.61
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-3.57
FCFYN/A
OCF(TTM)-3.57
OCFYN/A
SpS1.28
BVpS1.33
TBVpS1.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.44%
ROE -269.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.44%
FCFM N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 2.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.64
Quick Ratio 4.42
Altman-Z -1.78
F-Score4
WACC8.49%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y14.66%
EPS Next 2Y23.95%
EPS Next 3Y24.84%
EPS Next 5Y21.57%
Revenue 1Y (TTM)597.19%
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%266.97%
Revenue Next Year73.17%
Revenue Next 2Y93.15%
Revenue Next 3Y78.88%
Revenue Next 5Y57.94%
EBIT growth 1Y4.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.85%
EBIT Next 3Y23.51%
EBIT Next 5YN/A
FCF growth 1Y-118.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.43%
OCF growth 3YN/A
OCF growth 5YN/A

SYNDAX PHARMACEUTICALS INC / SNDX FAQ

What is the ChartMill fundamental rating of SYNDAX PHARMACEUTICALS INC (SNDX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SNDX.


What is the valuation status of SYNDAX PHARMACEUTICALS INC (SNDX) stock?

ChartMill assigns a valuation rating of 1 / 10 to SYNDAX PHARMACEUTICALS INC (SNDX). This can be considered as Overvalued.


Can you provide the profitability details for SYNDAX PHARMACEUTICALS INC?

SYNDAX PHARMACEUTICALS INC (SNDX) has a profitability rating of 1 / 10.


Can you provide the financial health for SNDX stock?

The financial health rating of SYNDAX PHARMACEUTICALS INC (SNDX) is 3 / 10.


What is the earnings growth outlook for SYNDAX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of SYNDAX PHARMACEUTICALS INC (SNDX) is expected to grow by 14.66% in the next year.